Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Amgen Submits Supplemental BLA For BLINCYTO® (Blinatumomab)
Amgen announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for BLINCYTO® (blinatumomab) to include new data supporting the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). BLINCYTO, the first-and-only FDA-approved bispecific CD19-directed CD3 T cell engager (BiTE®) immunotherapy, is currently available under an accelerated approval in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL, a rare and rapidly progressing cancer of the blood and bone marrow impacting both adults and children.

[adsense:336x280:8701650588]
- Read more about Aurinia receives Fda fast track designation for Voclosporin
Aurinia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for voclosporin, the Company’s next generation calcineurin inhibitor, for the treatment of Lupus Nephritis (LN).
- Read more about U.S. FDA Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). Odefsey is Gilead’s second TAF-based regimen to receive FDA approval and represents the smallest pill of any single tablet regimen for the treatment of HIV.
- Read more about Zydus Cadila received USFDA nod for Glyburide and Metformin
Zydus Cadila has received the final approval from the USFDA to market Glyburide and Metformin Hcl Tablets USP in strengths of 1.25/250, 2.5/500 and 5/500 mg.
- Read more about El Nino may transport cholera-like diseases: Study
El Nino, the climate cycle that develops along the tropical west coast of South America every 3 to 7 years, could be transporting cholera-like diseases through bacteria that thrive in seawater, a study said.
- Read more about Regular exercise may cut depression post-heart attack
People who exercise regularly over several years were less than half as likely to become depressed after a heart attack than those who never exercised, finds a new study.
- Read more about Infosys offers healthcare analytics on Microsoft cloud
Software major Infosys on Tuesday announced tying up with Microsoft to offer healthcare analytics, using the latter's cloud platform.
- Read more about 3,000 generic medicine stores to open: Jaitley
The government will set up 3,000 new generic medicine stores across the country to tackle the shortage of drugs in rural areas, Finance Minister Arun Jaitley said on Monday.
- Read more about Prolonged stress may cause memory loss
US researchers have found there is a relationship between prolonged stress and memory loss.The results of the study showed that those who were repeatedly exposed to stress had a trouble with spatial memory.
- Read more about Vitamin D deficiency linked to aggressive prostate cancer
Low levels of vitamin D in men can predict aggressive prostate cancer identified at the time of surgery, new research has found.